AWARDS AND RECOGNITIONS
CLARA D. BLOOMFIELD, MD, Distinguished University Professor, cancer scholar and senior adviser to the OSUCCC – James, was awarded the 2012 Richard L. Schilsky Cancer and Leukemia Group B Achievement Award at the Alliance for Clinical Trials in Oncology Group Meeting. The award acknowledges the significant contributions of an individual to cooperative group research.
ARNAB CHAKRAVARTI, MD, professor and chair of Radiation Oncology and co-director of the Brain Tumor Program, has been inducted as a fellow of the American College of Radiation Oncology in recognition of his contributions to the field of Radiation Oncology.
CARLO CROCE, MD, director of Human Cancer Genetics and chair of the Department of Molecular Virology, Immunology and Medical Genetics, received the Association for Molecular Pathology Award for Excellence in Molecular Diagnostics. The award recognizes
extraordinary achievement in the
fields of molecular biology, molecular pathology, pathology, genetics, microbiology and basic medical sciences. Croce will also receive the 2012 Anthony Dipple Carcinogenesis Awardsat the 2012 Biennial Congress of the European Association for Cancer Research in Barcelona, Spain in July. The award goes to individuals who have made major contributions to research in carcinogenesis. A paper by Croce and colleagues, titled “microRNA Involvement in Human Cancer,” was published in the June issue of the journal Carcinogenesis.
JOANNE LESTER, PhD, CRNP, ANP-BC, AOCN, a member of the Cancer Control Program at the OSUCCC – James, is a co-recipient of the 2012 Oncology Nursing Society Excellence in Survivor Advocacy Award.
GAIL DAVIDSON, RN, BSN, OCN, disease management coordinator in Surgical Oncology, has won the Oncology Nursing Society’s 2012 Excellence in Surgical Oncology Nursing Award. The award recognizes excellence of nursing contributions to surgical oncology.
RICHARD GOLDBERG, MD, physician-in-chief at the OSUCCC – James, was selected to deliver the first Charles G. Moertel Lecture to be presented through the newly formed Alliance for Clinical Trials in Oncology. during the plenary session of the Alliance’s June meeting. The Alliance was created from the merger of the North Central Cancer Treatment Group (NCCTG), Cancer and Leukemia Group B (CALGB) and the American College of Surgeons Oncology Group. Goldberg’s lecture was titled “Meaningful Outcomes: Lives Saved Due To Clinical Trials In Early-Stage Colon Cancer.”.
MICHAEL GREVER, MD, professor and chair of the Department of Internal Medicine and co-leader of the OSUCCC – James Experimental Therapeutics Program, has received the Philip S. Hench Distinguished Alumnus Award from the University of Pittsburgh School of Medicine’s Medical Alumni Association. The award is presented annually to a graduate of the School of Medicine and is the highest honor the alumni association confers upon one of its members.
NINA A. MAYR, MD, professor of Radiation Oncology, has been inducted as a Fellow of the American Society for Radiation Oncology. The ASTRO Fellows program recognizes service to ASTRO and outstanding contributions to the field of radiation oncology.
ELECTRA PASKETT, PhD, MSPH, Marion N. Rowley Professor of Cancer Research, director of the Division of Cancer Prevention and Control and associate director for population sciences at the OSUCCC – James, delivered the Jimmie Holland Lecture at the Alliance for Clinical Trials in Oncology Group Meeting. Her lecture was entitled Interventions to Address Cancer Health Disparities: The Case of Cervical Cancer in Appalachia.
FACULTY AND PROGRAMS
THOMAS LUDWIG, PhD, has joined the cancer program as a visiting associate professor of Molecular and Cellular Biochemistry. His research interests include the functional analysis and consequences of loss of the breast-cancer genes BRCA 1 and BRCA 2 in animal models.
JULIA WHITE, MD, has joined the cancer program as a professor of Radiation Oncology and director of Breast Radiation Oncology. at the Stefanie Spielman Comprehensive Breast Center.
TIMOTHY WRIGHT, has joined The Ohio
State University to lead the drug discovery institute that is being initially developed within the cancer program.
THE OHIO STATE UNIVERSITY’S MEDICAL CENTER has been renamed by the Board of Trustees as The Ohio State University Wexner Medical Center.
THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER, has opened the Center for Regenerative Medicine and Cell-Based Therapies. The Center is a collaboration of the colleges of Medicine, Engineering, Dentistry, Nursing, Veterinary Medicine, Arts and Sciences, and Pharmacy.
THE FINAL BEAM FOR THE NEW JAMES CANCER HOSPITAL AND SOLOVE RESEARCH INSTITUTE was riveted into place May 21.
A NEW CLINICAL TRIALS SEARCH TOOL, is available to anyone wanting to learn about active clinical trials at the OSUCCC – James. Or visit http://cancer.osu.edu and click on the red “search clinical trials” link.
DANILO PERROTTI, MD, PhD, associate professor in the Department of Molecular Virology, Immunology and Medical Genetics, and a member of the Molecular Biology and Cancer Genetics Program at the OSUCCC – James,has received a five-year, $1.52 million grant from the NCI to study the “Role of microRNAs in the Regulation of CML Stem Cell Survival and Self-Renewal” (grant CA163800).
LEADERSHIP ACTIVITIES AND APPOINTMENTS
TANIOS BEKAII-SAAB, MD, assistant professor of Medicine and of Pharmacology, and medical director of Gastrointestinal Oncology, has been accepted to the American Society of Clinical Oncology’s (ASCO) Leadership Development Program which prepares mid-career oncologists for leadership positions within ASCO.